Fluicell AB (publ) (STO:FLUI)
Sweden · Delayed Price · Currency is SEK 30.30
0.00 (0.00%)
Sep 24, 2026, 5:18 PM CET
Fluicell AB Revenue
Fluicell AB had revenue of 8.70M SEK in the quarter ending June 30, 2026, with 145.72% growth. This brings the company's revenue in the last twelve months to 25.51M, up 57.06% year-over-year. In the year 2025, Fluicell AB had annual revenue of 15.51M with 46.79% growth.
Revenue (ttm)
25.51M
Revenue Growth
+57.06%
P/S Ratio
2.26
Revenue / Employee
1.68M
Employees
11
Market Cap
41.62M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 15.51M | 4.94M | 46.79% |
| Dec 31, 2024 | 10.57M | 5.94M | 128.16% |
| Dec 31, 2023 | 4.63M | -2.41M | -34.24% |
| Dec 31, 2022 | 7.04M | 3.05M | 76.49% |
| Dec 31, 2021 | 3.99M | -880.00K | -18.07% |
| Dec 31, 2020 | 4.87M | 2.28M | 87.96% |
| Dec 31, 2019 | 2.59M | 1.37M | 111.34% |
| Dec 31, 2018 | 1.23M | 150.00K | 13.94% |
| Dec 31, 2017 | 1.08M | -1.58M | -59.43% |
| Dec 31, 2016 | 2.65M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Magle Chemoswed Holding AB | 275.79M |
| ExpreS2ion Biotech Holding AB | 24.25M |
| Biovica International AB | 14.93M |
| AcouSort AB | 9.31M |
| OncoZenge AB | 5.97M |
| Spago Nanomedical AB | 3.81M |
| Pila Pharma AB | 275.74K |
| Alzinova AB | 149.00K |
Fluicell AB News
- 27 days ago - Fluicell AB Quarterly report: Q2 2026 - Filings
- 4 months ago - Fluicell AB Quarterly report: Q1 2026 - Filings
- 7 months ago - Fluicell AB Annual report: Q4 2025 - Filings
- 7 months ago - Fluicell AB Quarterly report: Q4 2025 - Filings
- 10 months ago - Fluicell AB Quarterly report: Q3 2025 - Filings